HURA — TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 19
- Website: http://www.tuhurabio.com
Latest SEC filings for HURA
- 8-K — 2026-10-16
- 8-K — 2026-09-24
- 8-K — 2026-09-17
- 8-K/A — 2026-09-17
- 8-K — 2026-09-16
- 8-K — 2026-09-04
- SCHEDULE 13D/A — 2026-08-28
- 8-K — 2026-08-21
- 8-K — 2026-08-19
- 8-K — 2026-08-14
Latest HURA news
- — TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 (prnewswire.com)
Educational tool only — not investment advice.